Oncology (all articles)
Randomized trial: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
25 Jan, 2021 | 01:13h | UTCFirst-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
25 Jan, 2021 | 01:11h | UTC
Randomized trial of Irinotecan and Cetuximab with or without Vemurafenib in BRAF-Mutant metastatic colorectal cancer
22 Jan, 2021 | 07:57h | UTCCommentary: Triple chemotherapy combination improves metastatic colorectal cancer outcomes – SWOG AND Three Drugs Top Two for BRAF+ Metastatic Colorectal Cancer – MedPage Today
Final overall survival results of the IDEA Collaboration: 3 vs 6 months of adjuvant chemotherapy for Stage III Colon Cancer
22 Jan, 2021 | 07:58h | UTCOriginal article: Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
https://twitter.com/NatRevClinOncol/status/1334157879767568384
Cohort study: Recipients of hematopoietic stem-cell transplantation who develop COVID-19 have poor overall survival
21 Jan, 2021 | 01:18h | UTC
[Abstract Only] Meta-analysis: Myelodysplastic syndrome and acute myeloid leukemia in patients treated with PARP inhibitors
21 Jan, 2021 | 00:37h | UTCMyelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database – The Lancet Haematology (link to abstract – $ for full-text)
Commentary on Twitter
NEW research: a safety meta-analysis of RCTs and a retrospective study of the WHO pharmacovigilance database shows an increased risk of myelodysplastic syndrome and acute myeloid leukaemia in patients treated w/ PARP inhibitors #MDSsm #leusm https://t.co/evYF1ozg6c
— The Lancet Haematology (@TheLancetHaem) December 21, 2020
An epidemic of overdiagnosis: Melanoma diagnoses sky rocket
20 Jan, 2021 | 01:30h | UTCAn epidemic of overdiagnosis: Melanoma diagnoses sky rocket – Brigham and Women’s Hospital AND Does Screening for Skin Cancer Result in Melanoma Overdiagnosis? – Univadis
Original study: The Rapid Rise in Cutaneous Melanoma Diagnoses ($)
Related: Overdiagnosis: what it is and what it isn’t – BMJ Evidence Based Medicine (free) AND Overdiagnosis across medical disciplines: a scoping review – The BMJ Open (free) AND Too much medical care: bad for you, bad for health care systems – STAT News (free) AND Screening: How overdiagnosis and other harms can undermine the benefits – Health News Review (free) AND Overdiagnosis: causes and consequences in primary health care – Canadian Family Physician (free) AND Five warning signs of overdiagnosis – The Conversation (free) AND What is overdiagnosed cancer? And why does it matter? – Croakey (free) AND Blame rising cancer overdiagnosis on ‘irrational exuberance’ for early detection – STAT (free) AND Preventing overdiagnosis and the harms of too much sport and exercise medicine – British Journal of Sports Medicine (free)
Study: Similar length of hospital stay with laparoscopic vs. open gastrectomy for gastric cancer
20 Jan, 2021 | 01:05h | UTCLength of Hospital Stay With Laparoscopic vs Open Gastrectomy for Gastric Cancer – The ASCO Post
Meta-analysis: Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases
20 Jan, 2021 | 01:09h | UTC
IDH inhibitor Ivosidenib improves overall survival in previously treated patients with cholangiocarcinoma
20 Jan, 2021 | 01:08h | UTC
Postsurgical disease recurrence in stage I to III colorectal cancer may be predicted by ctDNA
20 Jan, 2021 | 01:07h | UTCCommentaries: Postsurgical Disease Recurrence in Stage I to III Colorectal Cancer May Be Predicted by ctDNA – The ASCO Post AND Liquid Biopsy Predicts Colon Cancer Relapse Months Before CT – MedPage Today (free registration required)
Randomized trial: Ultra-hypofractionated vs. conventionally fractionated radiotherapy for prostate cancer
19 Jan, 2021 | 01:14h | UTCUltra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Position paper: Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors
17 Jan, 2021 | 22:07h | UTC
Study shows sharp decline in cancer screenings and diagnoses during the first COVID-19 surge
17 Jan, 2021 | 21:57h | UTCOriginal study: Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic – JAMA Oncology
Nutrition in cancer care: A brief, practical guide with a focus on clinical practice
17 Jan, 2021 | 21:37h | UTC
CSCO and ASCO Guideline: Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma
15 Jan, 2021 | 08:14h | UTC
Randomized trial: Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma
15 Jan, 2021 | 08:12h | UTCOnce-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Triplet therapy slows refractory multiple myeloma – MedicalXpress
Systematic review: Adding abiraterone acetate to androgen deprivation therapy for the treatment of metastatic hormone-sensitive prostate cancer
15 Jan, 2021 | 08:10h | UTC
Systematic review: Immunotherapy vs. chemotherapy for people with advanced non-small cell lung cancer who have not been previously treated
14 Jan, 2021 | 01:30h | UTC
#Immunotherapy vs #chemotherapy for people with advanced non‐small cell #lungcancer who have not been not previously been treated https://t.co/RJlDp1SHTc New @CochraneLibrary systematic review includes 7 studies with 5893 participants.
— The Cochrane Library (@CochraneLibrary) December 21, 2020
Cancer Statistics, 2021. Cancer mortality dropping due to improved lung cancer treatment
14 Jan, 2021 | 01:33h | UTCCancer Statistics, 2021 – CA: A Cancer Journal for Clinicians
Commentary on Twitter
https://twitter.com/CAonline/status/1349020525889282062
NCCN Guideline: Genetic/familial high-risk assessment: breast, ovarian, and pancreatic
14 Jan, 2021 | 01:28h | UTC
Randomized trial: Adjuvant capecitabine in triple-negative breast cancer
13 Jan, 2021 | 01:40h | UTCCommentaries: Capecitabine maintenance may improve TNBC outcomes – medwire News
Commentary on Twitter
In this RCT, low-dose #capecitabine maintenance therapy for 1y resulted in improved 5-y disease-free survival vs observation among women with early-stage triple-negative breast cancer who received standard adjuvant treatment https://t.co/sIgxUSjaYe #BCSM #SABCS20 #VisualAbstract
— JAMA (@JAMA_current) January 6, 2021
Systematic review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
13 Jan, 2021 | 01:37h | UTC
Blueprint for cancer research: Critical gaps and opportunities
13 Jan, 2021 | 01:36h | UTCBlueprint for cancer research: Critical gaps and opportunities – CA: A Cancer Journal for Clinicians
Randomized trial: Early interdisciplinary supportive care in patients with previously untreated metastatic esophagogastric cancer
12 Jan, 2021 | 01:36h | UTC
Commentaries on Twitter
RCT of early interdisciplinary supportive care (ESC) in metastatic esophagogastric cancer
ESC by oncologists, dietitians & psychologists
⬆️ chemo cycles from 4 to 5
⬆️ OS HR=0.68
➡️ PFS
↗️ QoL
To be considered in radiochemotherapy #radonchttps://t.co/G6WQS8ULCb— Matthias Guckenberger (@Mat_Guc) January 10, 2021
Impressive survival benefit for early integrated multidisciplinary nutritional and psychological support vs. standard of care in Phase III trial for metastatic esophagogastric cancers in @ASCO_pubs. Intervention 14.8 mo vs. SOC 11.9 mo. https://t.co/FWE6xlPH8v
— Michael Shusterman, MD (@guildsman) January 9, 2021